中国晚期乳腺癌临床诊疗专家共识（2018版）

Chinese expert consensus on the clinical diagnosis and treatment of advanced breast carcinoma （2018）

乳腺癌是全球女性最常见的恶性肿瘤，2015年中国新发乳腺癌病例约27.2万，死亡约7万余例。在每年新发乳腺癌病例中，约3%～10%的妇女在确诊时即有远处转移。早期患者中，30%～40%可发展为晚期乳腺癌，5年生存率仅20%，总体中位生存时间为2～3年。晚期乳腺癌目前虽难以治愈，但可通过研发新型治疗药物、优化治疗模式等方法来缓解患者的临床症状，改善患者的生活质量，进一步延长患者的生存时间。晚期乳腺癌患者在治疗方案的选择方面有其特殊性，且多线治疗后进展的难治性乳腺癌的治疗缺乏标准推荐。中国乳腺癌诊疗专家共识组对不可手术的局部晚期和复发或转移性乳腺癌诊断、治疗及预后等方面国内外的相关研究数据进行分析、总结和讨论，制订出《中国晚期乳腺癌临床诊疗专家共识（2018版）》，以供临床医师参考。

Breast cancer is the most common malignant tumor among women in the world. In 2015, there were about 272 000 new diagnosed cases and over 70 000 deaths of breast cancer in China. In new cases of breast cancer each year, about 3 to 10 percent have distant metastases at the time of diagnosis. Among the early-stage patients, 30%-40% will develop into advanced breast cancer. The 5-year survival rate of patients with the advanced breast cancer is only 20%, and the overall median survival is 2-3 years. A/though advanced breast cancer is still difficult to cure at present, we can relieve the clinical symptoms, improve the quality of life and further prolong the survival time through development of new drugs and the optimization model of treatment. Patients with advanced breast cancer have their own particularity in the choice of treatment options. Moreover, there is no standard recommendation for the treatment of refractory breast cancer after muhiline therapy. In order to offer reference for clinicians, the Chinese expert group has analyzed, summarized and discussed the related research data of diagnosis, treatment and prognosis of inoperable locally advanced breast cancer and recurrent or metastatic breast cancer, and developed the Chinese expert consensus on the clinical diagnosis and treatment of advanced breast carcinoma （2018）.